PRELIMINARY SCIENTIFIC PROGRAMME

 

PLENARY LECTURES

A network-oriented view of living systems to complement the reductionist
Andrew Kasarskis, New York, U.S.A.

Is it time for one-person trials?
Nicholas Schork, La Jolla, U.S.A.

Transplantation tolerance: can it turn into a reality?
Kathryn Wood, Oxford, United Kingdom
 
MINI LECTURES
 

The endothelial surface layer and the development of glomerular disease
Ton J. Rabelink, Leiden, The Netherlands

Fundamental mechanisms of osmosis - revisited
Johann Morelle, Brussels, Belgium

Inflammation, immunity and hypertension
Speaker to be confirmed

How to improve HD outcome in children: more convection, more time, more sessions?
Michel Fischbach, Strasbourg, France

Role of stem cells in kidney regeneration
Michal Chmielewski, Gdansk, Poland

Testing for mutations in FSGS: should every patient undergo it?
Speaker to be confirmed

Directly acting anti-HCV agents: ready for use in CKD/ESRD?
Michel Jadoul, Brussels, Belgium

The value of kidney biopsy for the choice of therapy in patients with chronic GN
Loreto Gesualdo, Bari, Italy

Anti PLA2R antibodies and outcome of membranous nephropathy
Elion Hoxha, Hamburg, Germany

Guidelines in nephrology: what was expected? What was achieved?
Garabed Eknoyan, Houston, U.S.A.

Are international guidelines relevant in low and middle income countries?
Faiçal Jarraya, Sfax, Tunisia

The future impact of schistosomal nephropathies
Rashad Barsoum, Cairo, Egypt

How to prescribe Metformin in CKD
Marc E. De Broe, Antwerp, Belgium

Potential anti-ageing interventions in CKD
Peter Stenvinkel, Stockholm, Sweden

Iron supplementation and infections
Gert Mayer, Innsbruck, Austria

Blood pressure management in patients with CKD
Ivan Rychlik, Prague, Czech Republic

Vitamin D for better survival in CKD - any evidence?
David Goldsmith, London, United Kingdom

Uremic toxins - how far did we come in 2016?
Angel Argiles Ciscart, Montpellier, France

How valid are surrogate endpoints in nephrology research?
Carmine Zoccali, Reggio Calabria, Italy

Cardiovascular complications in CKD patients - what we have learned during the last 10 years?
Petar Kes, Zagreb, Croatia

Post-translational molecule modifications in uremia - only a biochemical issue?
Danilo Fliser, Homburg/Saar, Germany

Interventions to reduce progression of CKD - what is the evidence?
John Feehally, Leicester, United Kingdom

The emerging role for bone alkaline phosphatase isoforms in chronic kidney disease - mineral and bone disorder
Mathias Haarhaus, Stockholm, Sweden

Does calcium dialysate matter?
Ercan Ok, Izmir, Turkey

Haemodynamic modifications induced by dialysis vascular access
Carlo Basile, Taranto, Italy

The wearable kidney device: where do we stand in 2016?
Claudio Ronco, Vicenza, Italy

Peritoneal dialysis - what is new in 2016?
Monika Lichodziejewska-Niemierko, Gdansk, Poland

Mesenchymal stem cells as a potential pretransplant desensitization tool
Speaker to be confirmed

Challenges of transplant rejection diagnosis
Kerstin Amann, Erlangen, Germany

Blood pressure variability and the kidney
Mustafa Arici, Ankara, Turkey

Clinical studies that target inflammation in diabetic nephropathy
Peter Rossing, Gentofte, Denmark

Management of hyponatremia - what do the guidelines say?
Goce Spasovski, Skopje, F.Y.R. of Macedonia

Antonino D’Antona and the first description in 1909 of the crush syndrome with renal failure after the Messina earthquake
Natale Gaspare De Santo, Naples, Italy

In collaboration with the International Association for the History of Nephrology (IAHN)
IAHN
 
SYMPOSIA
 
Track 1
Fluid and electrolytes, tubular transport, physiology
 
When cell biology meets tubular transport
mTOR and autophagy in tubular health and injury
Tobias Huber, Freiburg, Germany
The endolysosomal system in the proximal tubule
Olivier Devuyst, Zurich, Switzerland
Regulation of sodium channel trafficking
Olivier Staub, Lausanne, Switzerland
Cell biology of collecting duct water transport
Robert Fenton, Aarhus, Denmark
 
Sensing mechanisms in nephrology
Calcium-sensing in the kidney
Pascal Houillier, Paris, France
Phosphate
J. Mariano Rodriguez, Cordoba, Spain
Renal and extrarenal sensing of acid-base
Carsten Wagner, Zurich, Switzerland
Potassium
David Ellison, Portland, U.S.A.
 
Hypoxia in kidney disease: integrating pre-clinical with clinical research
Oxygen sensing in the kidney
Volker Haase, Nashville, U.S.A.
Development of novel drugs targeting renal hypoxia and anaemia
Masaomi Nangaku, Tokyo, Japan
Imaging oxygen metabolism: new finding in both animal and human studies
Christoffer Laustsen, Aarhus, Denmark
MRI paradigms to assess renal haemodynamics and oxygenation in human studies
Speaker to be confirmed
 
Track 2
Hereditary disorders, development, pregnancy, paediatric nephrology
 
Actualities in hereditary disorders
ADPKD in children: new perspectives
Francesco Emma, Rome, Italy
Genetic testing for rare disorders: practical steps
Nine V.A.M. Knoers, Utrecht, The Netherlands
Inherited tubulopathies
Olivier Devuyst, Zurich, Switzerland
Ciliopathies and cystic disorders
Carsten Bergmann, Ingelheim am Rhein, Germany
 
Dialysis and transplantation in children
Optimising BP control in CKD and dialysis patients
Fabio Paglialonga, Milan, Italy
What have we learnt from peritoneal membrane biopsies: bench to bedside
Claus Peter Schmitt, Heidelberg, Germany
CKD-MBD in children: is bone disease the heart of the problem?
Rukshana Shroff, London, United Kingdom
Corticosteroid-free kidney transplantation
Ryszard Grenda, Warsaw, Poland
 
Development and pregnancy
CAKUT
Speaker to be confirmed
Renal progenitor cells to model inherited disorders
Paola Romagnani, Florence, Italy
Immunisation in pregnancy leads to membranous nephropathy
Pierre Ronco, Paris, France
Pathophysiology of pre-eclampsia
Matthew Hall, Nottingham, United Kingdom
 
Track 3
Glomerular diseases and general clinical nephrology
 
Kidney in systemic inflammatory diseases
B cell cytokine blockade in SLE
David Jayne, Cambridge, United Kingdom
New and old auto-antibodies for lupus nephritis
Gian Marco Ghiggeri, Genoa, Italy
Biologic drugs in the treatment of vasculitis
Vladimir Tesar, Prague, Czech Republic
New ways to interfere with the complement system
Giuseppe Remuzzi, Bergamo, Italy
 
What precipitates IgAN and what is the target for treatment?
Genetic determination in IgA Nephropathy
Krzysztof Kiryluk, New York, U.S.A.
The intestine-renal connection
Rosanna Coppo, Turin, Italy
Shall we treat intestinal immunity only?
Bengt Fellström, Uppsala, Sweden
Shall we treat the systemic inflammation? Lessons from STOP IgAN
Jürgen Floege, Aachen, Germany
 
Renal fibrosis: new insights
Perivascular progenitors, Hedgehog signaling and kidney fibrosis
Rafael Kramann, Aachen, Germany
The role of microvascular endothelium in progressive kidney disease
Bernd Hohenstein, Dresden, Germany
New mediators of renal fibrosis, or the road to therapy
Christos Chatziantoniou, Paris, France
Established mediators of renal fibrosis - where are the clinical trials?
Roel Goldschmeding, Utrecht, The Netherlands
 
Membranous nephropathy: new insights
The pathogenetic and clinical role of glomerular antigens in membranous nephropathy
Rolf A.K. Stahl, Hamburg, Germany
The PLA2R autoantigen: from pathophysiology to patients’ care
Pierre Ronco, Paris, France
Calcineurin inhibitors in membranous nephropathy
Manuel Praga, Madrid, Spain
Rituximab in membranous nephropathy
Piero Ruggenenti, Bergamo, Italy
 
Immunology and the kidney
OGN
NETs, histones and necroinflammation in kidney disease
Hans-Joachim Anders, Munich, Germany
T cells in glomerulonephritis
Kathrin Eller, Graz, Austria
Kidney dendritic cells in acute and chronic renal disease
Christian Kurts, Bonn, Germany
 
The gut-renal axis
OGN
Microbiome and inflammatory disease
Timothy Meyer, Palo Alto, U.S.A.
Gut microbiota and uremic toxins
Pieter Evenepoel, Leuven, Belgium
The nasal microbiome in granulomatosis with polyangiitis (GPA, Wegener’s)
Andreas Kronbichler, Innsbruck, Austria
IgAn and microbiota
Speaker to be confirmed
 
Track 4
CKD - Pathophysiology, epidemiology, prevention, progression, aging
 
Lingering questions in CKD
Is early nephrology care so important in stage 3b-4 CKD patients?
Goce Spasovski, Skopje, F.Y.R. of Macedonia
Is sleep apnea a really major problem in CKD?
Hypotheses and observations
Sydney Tang, Hong Kong, Hong Kong, P.R. China
Cardiac autonomic neuropathy in CKD patients with diabetes: relevant? preventable? treatable?
Speaker to be confirmed
 
Management of the frail and elderly with CKD
Nutritional status: evaluation and improvement
Denis Fouque, Lyon, France
Should dialysis be different in the frail elderly?
Olof Heimbürger, Stockholm, Sweden
Withholding and withdrawal of dialysis: models of care
Jacques Bernheim, Tel Aviv, Israel
Models for prediction of need for RRT vs risk of death in the elderly
Evi Nagler, Ghent, Belgium
 
Aging and CKD
EVA & ADAM: impact on aging kidneys
Alberto Ortiz, Madrid, Spain
BOLD MRI: a key measure to diagnose ischemic nephropathy
Menno Pruijm, Lausanne, Switzerland
Aortic aging in ESRD: structural, hemodynamic and mortality implications
Gérard London, Paris, France
New markers of frailty: myostatin
Thomas Bernd Dschietzig, Bensheim, Germany
 
Gone with the Wnt
Basics about Wnt signaling
Speaker to be confirmed
Wnt signaling in bone diseases
Martine Cohen-Solal, Paris, France
Limitations of the current therapies for osteoporosis in patients with CKD
Susan M. Ott, Seattle, U.S.A.
Sclerostin and the CV System
Vincent Brandenburg, Aachen, Germany
 
New aspects of sex hormones abnormalities in CKD patients
Testosterone deficiency - why it is important in male CKD patients
Mahmut Ilker Yilmaz, Ankara, Turkey
Hyperprolactinemia in CKD patients - friend or foe
Juan Jesus Carrero, Stockholm, Sweden
Female infertility in CKD and antimüllerian hormone
Marcin Adamczak, Katowice, Poland
Sexuality after successful kidney transplantation
Speaker to be confirmed
 
Novel oral anticoagulants or warfarin in CKD?
Is chronic anticoagulation treatment needed in chronic kidney disease?
Adrian Covic, Iasi, Romania
Do novel oral anticoagulants differ from vitamin K antagonists for efficacy or bleeding?
Jürgen Floege, Aachen, Germany
Stroke and bleeding in atrial fibrillation with chronic kidney disease
Anne Lise Kamper, Copenhagen, Denmark
Novel oral anticoagulants or warfarin in CKD ‐ a cardiologists perspective
Karolina Szummer, Stockholm, Sweden
 
Lipids in nephrology
OGN
Lipoproteins in Nephrology: clinical importance and therapeutic options
Kurt Derfler, Vienna, Austria
Compositional changes of lipids in CKD
Speaker to be confirmed
Lipid lowering in CKD: yes, no, maybe
Christoph Wanner, Würzburg, Germany
Lipids and CKD progression: myth or reality?
Alexander Rosenkranz, Graz, Austria
 
Bone, calcium and PTH in CKD
OGN
The rapidly exchangable calcium pool in hemodialysis patients
Markus Pirklbauer, Innsbruck, Austria
Clinical evaluation of bone: what makes sense?
Daniel Cejka, Vienna, Austria
What prophylaxis and therapy is really useful?
Sylvie Dusilova Sulkova, Hradec Kralove, Czech Republic
Uremic toxins and CKD-MBD
Ziad Massy, Paris, France
 
Track 5
End-stage renal disease, dialysis
 
Vascular access for HD
Pre-operative evaluation of vascular capital
Pedro Ponce, Lisbon, Portugal
Predictors of fistula function
Marko Malovrh, Radomlje, Slovenia
Non-pharmaceutical and pharmaceutical strategies to enhance fistula maturation and primary patency
Jan H. M. Tordoir, Maastricht, The Netherlands
Lock solutions to prevent clothing and infection in tunneled dialysis catheters
Laura Labriola, Brussels, Belgium
 
Nutrition in CKD patients
Metabolic rationale for enteral support
Speaker to be confirmed
Clinical trials update in CKD patients (including HD)
Wilfred Druml, Vienna, Austria
Should enteral support be identical in HD and PD?
Pieter M. Ter Wee, Amsterdam, The Netherlands
Low calorie diet in obese patients with CKD
Denis Fouque, Lyon, France
 
Calcification and calciphylaxis
Calcification in heart valves: clinical implications, consequences, therapy
Pablo Antonio Ureña Torres, Saint-Ouen, France
Evaluation of vascular calcifications
Speaker to be confirmed
New insights into the FGF23-Klotho axis
Tobias Larsson, Stockholm, Sweden
Uraemic calciphylaxis - clinical picture, course and therapeutic options
Markus Ketteler, Coburg, Germany
 
Personalized dialysis
Frequent or longer hemodialysis - benefits more than risks?
Pantelis A. Sarafidis, Thessaloniki, Greece
Dialysis modality choice in diabetic patients with end-stage kidney disease
Davide Bolignano, Reggio Calabria, Italy
Dialysis modalities and interventions to reduce intradialytic symptoms
Andrew Davenport, London, United Kingdom
Is online HDF the new standard for extracorporeal therapy?
Francesco Locatelli, Lecco, Italy
 
Whole person care in Nephrology
Uremic pruritus and xerosis
Jacek C. Szepietowski, Wroclaw, Poland
Wound care (including calciphylaxis)
Speaker to be confirmed
Fatigue in haemodialysis patients
Maurizio Bossola, Rome, Italy
Psychological care of patients with CKD
Marta Novak, Toronto, Canada
 
Track 6
Home therapies, peritoneal dialysis
 
PD clinical science
EuroPD
Bio-impedance: coming of age?
Speaker to be confirmed
Transition between modalities: what do we (not yet) know?
Christopher T. Chan, Toronto, Canada
Management of infections in PD
Anabela Rodriguez, Porto, Portugal
Outpatient peritoneal dialysis catheter insertion is safe and cost-saving
Speaker to be confirmed
 
Should PD as initial dialysis modality become the standard of care?
CKDopps: optimal timing of dialysis initiation and modality selection
Roberto Pecoits-Filho, Curitiba, Brazil
Urgent start of PD: PD first as standard of care?
James Heaf, Copenhagen, Denmark
How can residual renal function be preserved?
Sylvie Opatrná, Pilsen, Czech Republic
PDopps: optimizing PD and reducing technique failure rate
Speaker to be confirmed
 
Quality Improvement in PD (ISPD)
ISPD
Updates on ISPD Peritoneal Dialysis Infection Guidelines
Philip Li, Hong Kong, Hong Kong, P.R. China
Integrating geriatric care for older patients on PD
Edwina Brown, London, United Kingdom
ISPD Cardiovascular and Metabolic Guidelines
Rajnish Mehrotra, Seattle, U.S.A.
 
Track 7
Transplantation and immunology
 
Improving cardiovascular risk assessment in transplant patients
Metabolic risk factor profile before and after renal transplantation
Adnan Sharif, Birmingham, United Kingdom
Non-invasive cardiac imaging in the evaluation of kidney transplant candidates
Alan Jardine, Glasgow, United Kingdom
24h-ABPM in renal transplant patients: the nocturnal BP burden
Francesca Mallamaci, Reggio Calabria, Italy
How to approach post-transplant diabetes?
Marcus Säemann, Vienna, Austria
 
The living kidney donor
Development of CVD risk factors shortly after donation
Alaattin Yildiz, Istanbul, Turkey
The Oslo experience: long term risk after donation
Geir Mjøen, Oslo, Norway
Practice patterns for follow up of the kidney donors
Bruno Watschinger, Vienna, Austria
Psychological outcomes after living kidney donation
Hannah Maple, London, United Kingdom
 
Lingering issues in kidney transplantation
Pre-emptive kidney re-transplantation - If yes, when and for whom?
Maria Alicja Debska-Slizien, Gdansk, Poland
Immune surveillance after kidney transplantation
Martina Sester, Homburg/Saar, Germany
How to diminish the long-term renal allograft loss?
Marian Klinger, Wroclaw, Poland
 
How to handle the sensitized kidney transplant recipient
OGN
Precision diagnosis and risk stratification in kidney transplantation
Alexandre Loupy, Paris, France
Desensitization protocols: is there a favorite?
Georg A. Böhmig, Vienna, Austria
Treatment of ABMR: when to treat and what tools do we have?
Søren Schwartz Sørensen, Copenhagen, Denmark
Paired kidney donation
Ondrej Viklicky, Prague, Czech Republic
 
DGF: how to prevent it?
OGN

Intrarenal molecular events after death
Alberto Ortiz, Madrid, Spain
Integrational aspects of DGF - towards a rational treatment
Rainer Oberbauer, Vienna, Austria
Machine perfusion to preserve or to resuscitate: where are we today?
Ina Jochmans, Leuven, Belgium
Ischemic pre-conditioning in kidney transplantation outcomes: is time for a trial?
Daniel Abramowicz, Brussels, Belgium

 
Track 8
Hypertension, diabetes, vascular disease
 
Salt on the table
Salt consumption and cardiovascular disease: from etiology to prevention
Francesco Paolo Cappuccio, Coventry, United Kingdom
Salt consumption and renal outcomes
Speaker to be confirmed
Dialysate sodium: friend or foe?
Mustafa Arici, Ankara, Turkey
 
Uremic cardiomyopathy
Thick but weak: the pathophysiology of uremic cardiomyopathy
Kerstin Amann, Erlangen, Germany
Non-invasive assessment of cardiac structure and function - what nephrologists must know
Frank Flachskampf, Uppsala, Sweden
Clinical consequences: cardiac arrhythmia and SCD
Philip A. Kalra, Salford, United Kingdom
Future perspectives in the treatment of uremic cardiomyopathy
Marc Vervloet, Amsterdam, The Netherlands
 
Heart failure with preserved ejection fraction (HFPEF): the cardiorenal syndrome revisited

Pathogenesis
Loek Van Heerebeek, Amsterdam, The Netherlands
Diagnosis and prognostic implications of HFPEF in CKD
Gunnar Heine, Homburg/Saar, Germany
Therapy
Burkert Pieske, Berlin, Germany

 
Obesity and fat tissue – what is new and what is relevant for nephrologists?
New classification of obesity – not only BMI
Speaker to be confirmed
Obesity - a disease with many aetiologies disguised in the same oversized phenotype
Peter Stenvinkel, Stockholm, Sweden
Metabolic syndrome and renal outcome - a reappraisal
Andrzej J. Więcek, Katowice, Poland
Renal consequences of bariatric surgery - the downsides
Allon Friedman, Indianapolis, U.S.A.
 
Track 9
Acute kidney injury and intensive care nephrology
 
Cross-talk between kidneys and other organs in AKI
AKI and the heart
Claudio Ronco, Vicenza, Italy
AKI and the lung
Carmine Zoccali, Reggio Calabria, Italy
Novel evidence on the treatment of hepatorenal syndrome
Fabrizio Fabrizi, Milan, Italy
AKI in pregnancy
Fadi Fakhouri, Nantes, France
 
AKI - pathophysiology and definition
Biomarkers as a tool to understand pathophysiology of AKI
Jill Vanmassenhove, Ghent, Belgium
Looking through RIFLE, AKIN and KDIGO glasses: do we see the same?
Marlies Ostermann, London, United Kingdom
Acute intestitial nephritis: an overlooked cause of AKI?
Manuel Praga, Madrid, Spain
CKD imposed on AKI and vice versa
Mehmet Sukru Sever, Istanbul, Turkey
 
Fluid management in the ICU
Prevent the kidneys from drowning - How to assess fluid status in ICU patients
Jan T. Kielstein, Braunschweig, Germany
How to manage fluids in pediatric ICU patients?
Johan Vande Walle, Ghent, Belgium
In whom when which type of fluid: state of the art
Can Ince, Rotterdam, The Netherlands
Fluid overload at cardiac ICU: diuretics, slow ultrafiltration or peritoneal dialysis?
Speaker to be confirmed
 
Special technological aspects of ICU nephrology and extracorporeal treatment
CO2 removal: indications, outcomes, technology
Eric Hoste, Ghent, Belgium
Liver dialysis: technology, indications, outcomes
Achim Joerres, Berlin, Germany
ICU dialysis in the paediatric setting: outcomes and technological considerations
Franz Schaefer, Heidelberg, Germany
Extracorporeal treatment of immune mediated kidney disease
George Reusz, Budapest, Hungary
 
Special situations with need for nephrology advice
Prevention and management of AKI in the general ward: the UK experience
Nicholas Selby, Derby, United Kingdom
How and when (not) to dialyse the frail and elderlywith AKI
Wim Van Biesen, Ghent, Belgium
Pharmacokinetics of drugs in AKI and during RRT:what we should know?
Speaker to be confirmed
 
SPECIAL SYMPOSIA
 
Tomorrow´s nephrology presented by the nephrologists of tomorrow
(YNP – Young Nephrologists’ Platform)
YNP
Update on YNP initiatives
Ana Carina Ferreira, Lisbon, Portugal
Let´s talk about death! Regulated necrosis in acute kidney injury
Andreas Linkermann, Kiel, Germany
Immune monitoring in kidney transplant recipients
Speaker to be confirmed
Recent developments in atypical haemolytic uraemic syndrome
Speaker to be confirmed
 
ERA-EDTA Registry
ERA-EDTA Registry
Lifetime risk of Renal Replacement Therapy in Europe
Jan Van Den Brand, Nijmegen, The Netherlands
Transplanting kidneys from older deceased donors: a comparison of outcomes in young and old recipients
Maria Pippias, Amsterdam, The Netherlands
Vascular access in children on hemodialysis
Michael Böhm, Vienna, Austria
Prevalence of obese sarcopenia among elderly Stage 4 CKD patients and effect of muscle wasting on quality of life
Speaker to be confirmed
 
The Dialysis Outcomes and Practice
Patterns Study (DOPPS) Program:
Celebrating 20 Years and Looking Ahead
DOPPS
The DOPPS Program continues to grow and invites collaborators
Francesca Tentori, Ann Arbor, U.S.A.
Key lessons from the first 20 years of DOPPS
Michel Jadoul, Brussels, Belgium
Selected findings from the first EURODOPPS call for proposals
Karlijn van Stralen, Amsterdam, The Netherlands
CKDopps: Improving outcomes in advanced CKD and the transition to dialysis
Ziad Massy, Paris, France
PDOPPS: the largest international study of PD practices
Simon Davies, Stoke-on-Trent, United Kingdom
 
Ethics
 
Late Breaking Clinical Trials
 
NDT Polar Views
NDT
 
The Lancet
The Lancet
 
ERA-EDTA & European Society of Cardiology (ESC)
ESC
 
ERA-EDTA & European Society of Hypertension (ESH)
ESH
 
ERA-EDTA & European Society for Paediatric Nephrology (ESPN)
ESPN
 
ERA-EDTA & International Society of Nephrology (ISN)
ISN
 
ERA-EDTA & Japanese Society of Nephrology (JSN)
JSN
 
American Society of Nephrology Highlights (ASN)
ASN
 
MASTERCLASS
 
Managing PD patients - from basic principles to advanced practice
EuroPD
PD catheter: life line or strangling device?
Martin Wilkie, Sheffield, United Kingdom
Adequate PD prescription: balancing different interests
Speaker to be confirmed
 
CME COURSES
 
News in the diagnostics and treatment of glomerular disease
(IWG - Immunonephrology Working Group)
IWG
 
Practical issues in kidney transplantation
(DESCARTES Working Group - Developing Education Science and Care for Renal Transplantation in European States)
In collaboration with EKITA, a section of ESOT
Descartes
EKITA
 
A preview of the future in cardiovascular risk management in CKD
(EURECA-m Working Group - EUropean REnal and CArdiovascular Medicine)
EURECA-m
 
Hemodiafiltration - the new standard of care?
(Eudial Working Group - European Dialysis Working Group)
EUDIAL
 
Diabetes and obesity in renal disease
(DIABESITY - Working Group researching on the nephrological impact
in relation to diabetes and obesity)
Diabesity
 
As we grow old - nutritional considerations for the CKD elderly patient
(ERN – European Renal Nutrition Working Group)
ERN
 
Inherited Disorders: the kidney and beyond
(WGIKD - Working Group on Inherited Kidney Disorders)
WGIKD
 
New insights into CKD-MBD
(CKD-MBD Working Group)
CKD-MBD
 
Peritoneal dialysis in 2016 - where do we stand?
(EuroPD)
EuroPD
 
Uraemia: is it only a toxin affair? The emerging concept of networking
(EUTox Working Group - European Uremic Toxin)
EUTOX
 
Rheumatology for nephrologists
 
Disasters and the Nephrologist
 
Amyloidosis – old problem, new issues
 
Including the patient perspective in renal care
 
Transplantation immunology - an update
 
Non-pharmacological treatment of resistant hypertension – consensus for 2016
 
Less is more: why ‘treating to targets’ does not improve outcome of CKD patients?
 
Nephrolithiasis and CKD
(In collaboration with EULIS, the EAU Section of Urolithiasis)
EULIS
 
Crosstalk in renal epidemiology
(ERA-EDTA Registry)
ERA-EDTA Registry
 
Toxicology for nephrologists
 
Publishing Workshop